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ABSTRACT Bezlotoxumab is a human monoclonal antibody against Clostridium difficile
toxin B, indicated to prevent recurrence of C. difficile infection (rCDI) in high-risk adults
receiving antibacterial treatment for CDI. An exploratory genome-wide association study
investigated whether human genetic variation influences bezlotoxumab response. DNA
from 704 participants who achieved initial clinical cure in the phase 3 MODIFY I/II trials
was genotyped. Single nucleotide polymorphisms (SNPs) and human leukocyte antigen
(HLA) imputation were performed using IMPUTE2 and HIBAG, respectively. A joint test of
genotype and genotype-by-treatment interaction in a logistic regression model was
used to screen genetic variants associated with response to bezlotoxumab. The SNP
rs2516513 and the HLA alleles HLA-DRB1*07:01 and HLA-DQA1*02:01, located in the ex-
tended major histocompatibility complex on chromosome 6, were associated with the
reduction of rCDI in bezlotoxumab-treated participants. Carriage of a minor allele (ho-
mozygous or heterozygous) at any of the identified loci was related to a larger differ-
ence in the proportion of participants experiencing rCDI versus placebo; the effect was
most prominent in the subgroup at high baseline risk for rCDI. Genotypes associated
with an improved bezlotoxumab response showed no association with rCDI in the pla-
cebo cohort. These data suggest that a host-driven, immunological mechanism may im-
pact bezlotoxumab response. Trial registration numbers are as follows: NCT01241552
(MODIFY I) and NCT01513239 (MODIFY II).
IMPORTANCE Clostridium difficile infection is associated with significant clinical mor-
bidity and mortality; antibacterial treatments are effective, but recurrence of C. diffi-
cile infection is common. In this genome-wide association study, we explored
whether host genetic variability affected treatment responses to bezlotoxumab, a
human monoclonal antibody that binds C. difficile toxin B and is indicated for the
prevention of recurrent C. difficile infection. Using data from the MODIFY I/II phase 3
clinical trials, we identified three genetic variants associated with reduced rates of C.
difficile infection recurrence in bezlotoxumab-treated participants. The effects were
most pronounced in participants at high risk of C. difficile infection recurrence. All
three variants are located in the extended major histocompatibility complex on
chromosome 6, suggesting the involvement of a host-driven immunological mecha-
nism in the prevention of C. difficile infection recurrence.
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Clostridium difficile is a Gram-positive, spore-forming, toxigenic bacterium that over-grows in the large intestine due to treatment with broad-spectrum antibiotics or
due to disruptions in the normal gastrointestinal microbiome (1). C. difficile toxins (A
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and B) cause inflammation of the colon and can increase rates of morbidity and
life-threatening conditions, including severe diarrhea and pseudomembranous colitis
(1). In recent years, there has been a substantial increase in morbidity and mortality
related to C. difficile infection (CDI), with the Centers for Disease Control and Prevention
in the United States reporting a 400% increase in deaths between 2000 and 2007 (2),
in part due to the emergence of a more virulent C. difficile strain type (3).
Current antibacterial treatment for primary CDI includes the use of vancomycin or
fidaxomicin (4) and is often successful, with initial clinical cure rates commonly over
80% (5, 6). However, following antibacterial treatment, up to 25% of patients experi-
ence a first recurrent CDI (rCDI) (5–8). Of patients who experience rCDI, approximately
40% will have a second rCDI (7). This high rate of recurrence has been attributed to
intestinal microbiome dysbiosis following antibiotic treatment for CDI and the persis-
tence of C. difficile spores largely unaffected by antibacterials (9, 10). Patients at
increased risk for rCDI include those with a prior episode of CDI, with severe infection,
aged 65 years or more, immunocompromised, receiving concomitant antibiotics for
non-CDI infection, and with hypervirulent C. difficile strains (e.g., ribotypes 027, 078, and
244) (7, 8, 11–16).
The efficacy and safety of bezlotoxumab were evaluated in the MODIFY I/II phase 3
trials in participants receiving antibacterial drug treatment for primary or rCDI (17). A
single, 10-mg/kg (of body weight) intravenous dose of bezlotoxumab produced a
consistent reduction in rCDI over 12 weeks compared with placebo infusion (10% and
37.5% absolute and relative reduction, respectively) (17).
While genetic variants among C. difficile strains are known to influence virulence and
risks for mortality (18), little is known of the effects of host genetic variations on CDI and
specifically CDI treatment outcomes. Using data collected from the MODIFY I/II trials, an
exploratory genome-wide association study (GWAS) was conducted to investigate
whether genetic variants were associated with response to bezlotoxumab with the
specific aim of identifying genetic predictive biomarkers that could enable identifica-
tion of patient subpopulations who may have preferential benefit with bezlotoxumab
treatment. Identification of genetic markers that can predict treatment response may
also provide putative mechanistic insight into new disease biology around CDI.
RESULTS
Participants. In total, 2,655 participants were enrolled in the MODIFY I/II trials, of
whom 2,559 were included in the modified intention-to-treat (mITT) population (17).
One thousand one participants who consented to genetic sampling and passed GWAS
quality controls (QCs) were included as the pharmacogenetic (PGx) population. Of
these, 704 participants who were randomized to bezlotoxumab-containing or placebo
arms and achieved initial clinical cure were included in the PGx GWAS analyses. The
baseline characteristics and rCDI-related risk factors of the pharmacogenetic and mITT
populations from MODIFY I/II are listed in Table 1. The pharmacogenetic and mITT
populations were generally similar. The majority of participants (70%) had at least one
risk factor for rCDI, although the proportion was slightly smaller in the PGx population.
CDI-related outcomes were similar in the mITT and PGx populations when combining
all treatment arms (Table 1) and for each treatment arm (see Table S1 in the supple-
mental material).
HLA association analysis. Human leukocyte antigen (HLA) imputation identified
two class II alleles, HLA-DRB1*07:01 and HLA-DQA1*02:01, in high linkage disequilibrium
(LD, r2  0.98) that were also associated with bezlotoxumab treatment response to
rCDI. HLA-DRB1*07:01 (minor allele frequency [MAF] 0.10) was associated with rCDI
(P 1.93 105) such that the per-allele odds ratio (OR) (95% confidence interval [CI])
was 0.19 (0.06 to 0.44). Similarly, HLA-DQA1*02:01 (MAF 0.11) was associated with
rCDI (P 5.18 105) with a per-allele OR (95% CI) of 0.21 (0.08 to 0.46) (Table 2).
Genome-wide association analysis. After single nucleotide polymorphism (SNP)
imputation and QC, there were 7,570,264 variants available for GWAS analysis. The
common intergenic SNP rs2516513 (6:31447588, MAF 0.23) was associated with a
Shen et al.
May/June 2020 Volume 5 Issue 3 e00232-20 msphere.asm.org 2
reduction in rCDI in bezlotoxumab-treated participants (P 6.46 108; per-allele OR,
0.31; 95% CI, 0.18 to 0.48) (Table 2) but not in placebo-treated participants (per-allele
OR, 0.91; 95% CI, 0.57 to 1.44). The SNP rs2516513 joint test of genotype and genotype-
by-treatment interaction P value was 3.04 108, and the genotype-by-treatment
interaction P value was 4.44 105. Manhattan and QQ plots from the GWAS analysis
are shown in Fig. 1. SNP rs2516513 is located between the HCP5 and MICB genes in
the extended major histocompatibility complex (xMHC) on chromosome 6, as shown
in Fig. 2A. The rs2516513 T allele was carried by 41% of participants in the clinical
trial population, consistent with the allele frequency of this SNP in individuals of
European descent in the 1000 Genomes database (19). In addition to rs2516513,
two other SNPs in high LD (r2  0.99) were also associated with a reduction in rCDI
rate in bezlotoxumab-treated participants: rs113379306 (6:17333351, MAF 0.04;
P  3.54 108) and rs76166871 (6:17329940, MAF 0.04; P 4.64 108). How-
ever, after conditioning on rs2516513, these SNPs were not associated with rCDI risk in
bezlotoxumab-treated participants (Fig. 2B), indicating that SNP rs2516513 was the
TABLE 1 Participant characteristics and CDI-related outcomes in the overall and
pharmacogenetic populationsd
Characteristic or outcome
Value for populationc:
mITT (n 2,559) PGx (n 1,001)
Baseline characteristic
Age (yr)
Mean (SD) 63.3 (17.6) 61.9 (17.4)
Median 66 64
Range 18–100 18–99
Sex, female 1,444 (56.4) 598 (59.7)
65 yr of age 1,358 (53.1) 489 (48.9)
1 CDI episodes in past 6 months 704 (27.5) 286 (28.6)
2 previous CDI episodes ever 363 (14.2) 170 (17.0)
Severe CDI (Zar score 2)a 420 (16.4) 121 (12.1)
Immunocompromised 549 (21.5) 170 (17.0)
Charlson comorbidity index 3 1,054 (41.2) 360 (36.0)
Albumin 2.5 g/dl 332 (13.0) 104 (10.4)
Ribotype 027, 078, or 244 337 (21.1) 119 (18.9)
Antibiotic use during ADT 852 (33.3) 296 (29.6)
Antibiotic use after ADT 782 (30.6) 275 (27.5)
1 risk factor for rCDIb 1,941 (75.8) 706 (70.5)
Outcome
Initial clinical cure 1,814 (70.9) 704 (70.3)
rCDI 454 (25.0) 191 (27.1)
aZar score based on (i) age of 60 years (1 point), (ii) body temperature of 38.3°C (1 point), (iii) albumin
level of 2.5 g/dl (1 point), (iv) peripheral white blood cell count of 15,000 cells/l within 48 h (1 point),
(v) endoscopic evidence of pseudomembranous colitis (2 points), and (vi) treatment in an intensive care
unit (2 points).
bPrespecified risk factors for rCDI included age of 65 years; 1 CDI episodes in past 6 months; Zar score of
2; immunocompromised; ribotype 027, 078, or 244; and antibiotic use during/after ADT.
cData are presented as n (%) unless otherwise indicated.
dAbbreviations: ADT, antibacterial drug treatment for CDI; CDI, Clostridium difficile infection; mITT, modified
intent-to-treat; PGx, pharmacogenetic population; rCDI, recurrent Clostridium difficile infection.
TABLE 2 GWAS and HLA association resultsc
SNP/HLA
allele Chr MAF n Overall P valuea
BEZ and BEZ  ACT Placebo
P valueb  (SE) OR (95% CI) P valueb  (SE) OR (95% CI)
rs2516513 6 0.23 701 3.04  1008 6.46  1008 1.19 (0.25) 0.31 (0.18–0.48) 6.97  1001 0.09 (0.23) 0.91 (0.57–1.44)
HLA-DRB1*07:01 6 0.10 689 1.93  1005 1.65  1005 1.67 (0.48) 0.19 (0.06–0.44) 5.88  1001 0.17 (0.32) 1.19 (0.63–2.21)
HLA-DQA1*02:01 6 0.11 699 5.18  1005 1.80  1005 1.56 (0.44) 0.21 (0.08–0.46) 5.47  1001 0.19 (0.31) 1.21 (0.65–2.21)
aOverall P value (P value from joint test of genotype and genotype-by-treatment interaction).
bP value from 1-df test of SNP.
cAbbreviations: ACT, actoxumab; BEZ, bezlotoxumab; Chr, chromosome; CI, confidence interval; df, degree of freedom; GWAS, genome-wide association study; HLA,
human leukocyte antigen; MAF, minor allele frequency; OR, odds ratio; SNP, single nucleotide polymorphism.
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primary signal in this region. There was weak LD (r2  0.14) between rs2516513 and
HLA-DRB1*07:01.
Assessment of evidence for causal variant and gene. Fine-mapping of the GWAS
summary statistics at the rs2516513 locus identified 26 variants with posterior proba-
bility of causality of 1%, including the lead variant rs2516513. These variants are all
noncoding; therefore, we examined published gene expression, protein expression, and
methylation data to identify a potential causal gene(s) for the GWAS signal. To do this,
we assessed whether the lead GWAS SNP or any SNP in high LD (r2  0.8) was a
significant expression quantitative trait locus (eQTL), protein quantitative trait locus
(pQTL), or methylation quantitative trait locus (meth-QTL). These variants were linked to
26 genes by at least one of the data sources used (Table S2). Three genes were linked
to the locus by at least two of the data sources used: MICB, HCG27, and C4B. Further
Chromosome
0
2
4
6
8
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 2122
–l
og
10
(P
-v
al
ue
)
rs2516513 P = 3.04E-08
Expected –log10(P-value)
O
bs
er
ve
d 
–l
og
10
(P
-v
al
ue
)
0
2
4
6
8
A
B
0 1 2 3 4 65 7
FIG 1 Manhattan plot (A) and QQ plot (B) showing the significance of SNP rs2516513 associated with drug-induced reduction on rCDI
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FIG 2 Regional association plot of 500 kb on each side of the rs2516513 SNP before (A) and after (B) conditioning. SNP,
single nucleotide polymorphism.
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details regarding the cell or tissue types and directionality of association for these three
genes are included in Table S3.
Conditional association analysis. Conditional regression analyses further showed
that the signals from HLA-DRB1*07:01 and HLA-DQA1*02:01 were driven in large part by
signals from rs2516513. After conditioning on HLA-DRB1*07:01 and HLA-DQA1*02:01,
pairwise association P values for rs2516513 were 5.70 105 and 1.42 105, respec-
tively. The conditional association results of HLA-DRB1*07:01 and HLA-DQA1*02:01 were
similar, with P values of 0.014 and 0.037 (both0.05), respectively, while conditioning
on rs2516513, since they are in high LD with each other.
rCDI summarized by genotype and risk category. Demographic and clinical rCDI
risk factors were similar between participants with TT or TC genotypes (SNP) and
those with CC genotypes (SNP) and between participants with HLA-DRB1*07:01:HLA-
DRB1*07:01 or HLA-DRB1*07:01:X (HLA) and X:X (HLA) genotypes (Table S4). In
participants treated with bezlotoxumab who carried the T allele of SNP rs2516513 (i.e.,
TC or TT genotype), the rate of rCDI was reduced compared with participants in the
placebo group (21.5% absolute difference; two-sided Fisher’s exact test,
P 3.04 105) (Fig. 3A and Table S5). The effect of the T allele was most prominent
in the subgroup of bezlotoxumab-treated participants at high risk of rCDI (24.6%
absolute difference versus placebo; two-sided Fisher’s exact test, P 5.69 105). This
trend was less pronounced in the low-risk subgroup (10.6% absolute difference
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FIG 3 Proportion of participants with rCDI stratified by genotype and risk category. (A) rs2516513 genotype. (B)
HLA-DRB1*07:01 genotype. The high-risk subgroup included participants with one or more of the following factors:
prior episode of CDI in the past 6 months, severe CDI at baseline (per Zar score [37]), age of 65 years, CDI due
to a hypervirulent strain (027, 078, or 244 ribotypes), immunocompromised, or receiving concomitant systemic
antibiotics. Participants at low risk of rCDI were those with none of the above risk factors. P values were calculated
from two-sided Fisher’s exact tests. BEZ, bezlotoxumab; CDI, Clostridium difficile infection; HLA, human leukocyte
antigen; PBO, placebo; rCDI, recurrent Clostridium difficile infection.
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versus placebo, two-sided Fisher’s exact test, P 0.15), which may be due to the low
number (64) of participants and the low rate (6.25%) of rCDI in this subgroup. In CC
homozygous participants, rCDI rates exceeded 30% in both treatment groups and in
participants at high and low risk of rCDI (Fig. 3A).
Bezlotoxumab-treated participants who carried at least one HLA-DRB1*07:01 allele
also had a reduced rate of rCDI compared with placebo treatment (32.3% absolute
difference; two-sided Fisher’s exact test, P 1.95 105). This effect was also observed
in the high-risk subgroup (33.2% absolute difference versus placebo; two-sided
Fisher’s exact test, P 9.81 105) but not in the low-risk subgroup (28.3% absolute
difference versus placebo; two-sided Fisher’s exact test, P 0.085). Among noncarriers
of the HLA-DRB1*07:01 allele, no treatment differences in rCDI were observed in the
overall group or in high- or low-risk subgroups (Fig. 3B and Table S6).
As shown in Fig. 4, the reduction in risk of rCDI following bezlotoxumab treatment
versus placebo varied depending on the baseline risk category. Participants carrying
the rs2516513 T allele or the HLA-DRB1*07:01 allele exhibited a strong trend for benefit
of bezlotoxumab treatment in the high-risk rCDI category. In contrast, noncarriers of
the rs2516513 T allele or the HLA-DRB1*07:01 allele showed limited benefit from
bezlotoxumab treatment. Because only a small percentage of these participants were
in the low-risk subgroups (rs2516513 T allele, 64/701 [9%]; HLA-DRB1*07:01 allele,
29/689 [4%]), the CIs are wide and cross zero.
Risk Population %
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FIG 4 CDI recurrence stratified by genotypes and rCDI risk categories: rs2516513 genotype (A) and HLA-DRB1*07:01
genotype (B). The high-risk subgroup included participants with one or more of the following factors: prior episode
of CDI in the past 6 months, severe CDI at baseline (per Zar score [37]), age of65 years, CDI due to a hypervirulent
strain (027, 078, or 244 ribotypes), immunocompromised, or receiving concomitant systemic antibiotics. Partici-
pants at low risk of rCDI were those with none of the above risk factors. BEZ, bezlotoxumab; CDI, Clostridium difficile
infection; CI, confidence interval; PBO, placebo; rCDI, recurrent Clostridium difficile infection.
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DISCUSSION
These findings highlight the potential value of conducting GWAS analyses in phase
3 studies. Identifying a genetic signal during clinical development provides an early
indication of a potential treatment-predictive biomarker; furthermore, such a finding
allows for consideration of possible routes for validation and for recognition of poten-
tial new mechanisms that might enable further improvements in therapeutic interven-
tion.
This exploratory GWAS identified the T allele carriers of SNP variant rs2516513, and
HLA carriers of the alleles HLA-DRB1*07:01 and HLA-DQA1*02:01, as being associated
with a positive treatment response to bezlotoxumab relative to placebo (reduced rCDI
rate among allele carriers). The effects were most pronounced in participants deter-
mined to be at high risk for rCDI based on clinical factors used to determine likelihood
for rCDI. A smaller effect was seen in bezlotoxumab-treated participants at low risk for
rCDI with the same trend; however, statistical significance was not reached, possibly
due to the low numbers of participants in the low-risk category. In addition, bezlotox-
umab treatment responses in participants carrying both the SNP rs2516513 T allele and
the HLA-DRB1*07:01 allele were similar to those from carriers of each individual risk
allele (see Table S7 in the supplemental material). Furthermore, results from GWAS
sensitivity analysis using Caucasian-only participants were very similar to those from all
participants (Tables S5 and S6).
There was no correlation between clinical risk factors and genetic risk factors, as
easily ascertained risk factors for rCDI that were collected during the clinical trial were
similar in the SNP (rs2516513 TC or TT genotypes) and SNP (rs2516513, CC geno-
types) subgroups and the HLA (HLA-DRB1*07:01:HLA-DRB1*07:01 or HLA-DRB1*07:01:X)
and HLA (X:X) subgroups (Table S4). This indicates that currently known clinical and
demographic risk factors for rCDI are not likely to be useful as a surrogate to easily
define the genotype subgroups (for example, SNP or HLA genotype subgroups) who
would benefit from bezlotoxumab treatment.
While different baseline patient characteristics and variation in C. difficile strains are
known to influence the incidence of rCDI (7, 8, 11, 14, 18), there have been few studies
on the effects of host genetic polymorphisms on rCDI. One recent study of data
collected during a C. difficile outbreak at a tertiary care center found that host factors
were more important predictors for rCDI than strain type or use of antibiotics (20).
Moreover, an earlier prospective cohort study found that a common polymorphism in
the interleukin-8 promoter region was associated with an increased risk for rCDI, with
participants carrying the AA allele having an approximately 2-fold-greater risk of rCDI
than participants with AT or TT genotypes (21). However, we and others were unable
to replicate the interleukin-8 promoter finding in our study (see the supplemental
material) (22). Another study investigating primary toxigenic C. difficile colonization
found that a polymorphism in the Toll-like receptor 4, rs1927914, was independently
associated with colonization (23). Taken together, the previous studies suggest that use
of host genetic profiling may identify participants at high risk for rCDI. However, in this
study our findings suggest that we have identified genetic factors specifically associ-
ated with bezlotoxumab treatment response (i.e., with a strong predictive treatment
effect), which are not associated with rCDI (i.e., with prognostic effects related to CDI
recurrence).
The identification of bezlotoxumab treatment-associated genetic loci on chromo-
some 6 within the xMHC suggests the potential involvement of a host-driven, immu-
nological mechanism in response to bezlotoxumab treatment of rCDI. An intergenic
variant in the xMHC, rs2516513, was associated with treatment benefit. In other studies,
the SNP rs2516513 has been shown to associate with HIV-1 controllers and progressors
(24), suggesting that it may contribute to immune control of HIV. rs2516513 or variants
in high LD have been linked to mRNA or protein expression or methylation level of a
number of genes. For example, rs2516513 has been linked to increase in protein
expression of MICB in human plasma and mRNA expression in CD14 monocytes, as
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well as decreased expression in naive CD4 T cells and adipose, thyroid, and skin
tissues (see Table S3 in the supplemental material). MICB encodes MHC class I
polypeptide-related sequence B (MICB), a cell surface protein expressed in response to
stress that is recognized by certain types of T cells and natural killer cells (25). While the
function of MICB is not known, there is evidence that it plays a role in immune response
to pathogens (26). rs2516513 is also associated with a decrease in mRNA expression of
C4B, encoding complement component 4B, in naive CD4 T cells and an increase in
plasma protein levels (Table S3); the complement system plays a key role in innate
immune response. While the most likely causal genes at the locus are linked to immune
response and no association was observed in the placebo arm, further investigation is
required to determine the mechanism linking change in function of the causal gene
specifically to treatment response. More broadly, the rs2516513 locus can be linked to
a number of other genes, and further studies would be required to determine conclu-
sively the causal gene driving the association between this locus and response to
bezlotoxumab.
Two HLA alleles, HLA-DRB1*07:01 and HLA-DQA1*02:01, were also associated with
treatment benefit. HLA molecules play a pivotal role in the adaptive immune response,
binding peptide fragments from pathogens and displaying them on the cell surface for
recognition by T cells (27). They are also known for having a high level of genetic
polymorphisms, which likely enable the host to respond to a range of different and
rapidly evolving pathogens (27). Previous studies have indicated a link between
adaptive immune response to infection and protection from rCDI, with a serum
antibody response to C. difficile toxins being associated with subsequent protection
from recurrence (28). Furthermore, a study in MHC class II knockout mice and CD4
T-cell knockout mice found that protection from rCDI is dependent on antitoxin
antibody formation and requires MHC cass II genes (29). Bezlotoxumab has low
immunogenicity potential (30), suggesting that the association between specific HLA
alleles and response to treatment is not related to an immunogenic response against
bezlotoxumab itself, but rather a host response against infection that becomes impor-
tant specifically in subjects administered treatment. However, conditional analysis
indicates that the association with HLA alleles may be largely driven by the rs2516513
locus, rather than by an independent association driven by a particular HLA allele.
As the results of this study are purely exploratory, the findings cannot be considered
conclusive and require confirmation in an independent validation study. If these loci are
confirmed as predictive for response to bezlotoxumab, future research should also
focus on the mechanism underlying this effect.
In conclusion, this exploratory GWAS identified an SNP (rs2516513) and two HLA
alleles (HLA-DRB1*07:01 and HLA-DQA1*02:01) in the xMHC region on chromosome 6
associated with an approximately 2-fold- and 3-fold-decreased risk for rCDI in
bezlotoxumab-treated participants, respectively. These effects were most prominent in
participants at high risk for rCDI carrying either the rs2516513 T allele or the HLA-
DRB1*07:01 allele. A smaller (non-statistically significant) effect was seen in participants
at low risk for rCDI with the same trend. Further confirmation of these loci as predictors
for rCDI prevention with bezlotoxumab treatment needs to be performed.
MATERIALS AND METHODS
Study design. MODIFY I (trial registration no. NCT01241552) and MODIFY II (trial registration no.
NCT01513239) were randomized, double-blind, placebo-controlled, multicenter, phase 3 trials that were
conducted from 1 November 2011 to 22 May 2015 at 322 sites in 30 countries (17). Full details of the
studies have previously been published (17). Briefly, participants receiving oral metronidazole, vanco-
mycin, or fidaxomicin for 10 to 14 days for the treatment of primary CDI or rCDI were randomized to
receive an infusion of bezlotoxumab (10 mg/kg), actoxumab (10 mg/kg) (MODIFY I only), bezlotoxumab
plus actoxumab (10 mg/kg each), or placebo (0.9% saline). CDI was defined as 3 unformed bowel
movements (types 5 to 7 on the Bristol stool scale [31] in 24 h) with a stool test positive for toxigenic C.
difficile. Occurrence of rCDI within 12 weeks of follow-up was assessed in participants who achieved an
initial clinical cure, which was defined as no diarrhea during the two consecutive days following
completion of 16 calendar days of antibacterial drug treatment for CDI. rCDI was defined as a new
episode of CDI after initial clinical cure of the baseline episode.
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MODIFY I and II were conducted in accordance with Good Clinical Practice guidelines and the
provisions of the Declaration of Helsinki. The protocols and amendments were approved by the
institutional review board or independent ethics committee at each study site. Written informed consent
was provided by all participants before the trial began.
Genotyping, QC, and imputation. DNA was extracted from peripheral blood samples collected from
participants in MODIFY I/II who consented to PGx analyses. Genotyping was performed using an Axiom
array platform (Affymetrix Axiom array); genotype imputation was performed using the 1000 Genomes
phase 1 reference data and IMPUTE2 software (32), after standard GWAS QC but prior to the genetic
analysis. The details of the GWAS QC and SNP imputation are described in Text S1 and Fig. S1 in the
supplemental material. The HLA alleles in three class I loci (HLA-A, HLA-B, and HLA-C) and four class II loci
(HLA-DRB1, HLA-DQA1, HLA-DQB1, and HLA-DPB1) were prespecified for the association analysis and were
imputed using HLA Genotype Imputation with Attribute Bagging (HIBAG) (33). The best-guess imputed
HLA types were used by setting the call rate threshold to 0.5, meaning that the imputed genotypes were
set as missing if their imputation posterior probability was less than 0.5. The multiallelic HLA types were
converted to the biallelic HLA alleles for each unique HLA allele. The biallelic HLA alleles were then
recoded as 0, 1, and 2 to reflect the number of minor alleles carried by participants. For example, for the
allele HLA-A*11:01, genotypes X/X, HLA-A*11:01/X, and HLA-A*11:01/HLA-A*11:01 would be assigned as 0,
1, and 2, respectively. In total, 219 HLA alleles from three class I and four class II HLA genes were imputed
via HIBAG.
Statistical analysis. In PGx studies, a patient’s clinical outcomes are influenced by both prognostic
and predictive factors. A prognostic biomarker discovered by testing the genotype main effect affects the
likelihood of the clinical phenotype regardless of the type of treatment, which is useful in classifying
patients into different risk categories indicating the condition of the disease. In contrast, a predictive
biomarker discovered by testing the genotype-by-treatment interaction affects the likelihood of the
clinical event for a treatment, which is useful in segmenting patients into treatment response and
nonresponse groups. The joint test of the main genetic effect and the genotype-by-treatment interaction
effect usually increases power for detecting signals in PGx studies compared with only testing the
interaction effect or the main genotype effect separately (45). Thus, we used the 2-degree-of-freedom
(2-df) likelihood test (joint test of genotype and genotype-by-treatment interaction) P value as the screen
step to assess the combined prognostic and (treatment-related) predictive association of each genetic
variant to drug response (rCDI) and declare statistical significance in this randomized clinical trial GWAS
analysis with small sample size (n 704). In addition, we also generated the 1-df test of the main
genotype P value and the 1-df test of the main genotype-by-treatment interaction P value, the 1-df test
P value in the treatment (bezlotoxumab [BEZ] and BEZ actoxumab [ACT]) arm, and the 1-df test P value
in the placebo arm to help interpret the results.
To provide increased statistical power for the exploratory GWAS, data from the bezlotoxumab-
containing arms and placebo arms, respectively, were pooled across both MODIFY I/II trials. The
actoxumab-alone arm was not used in this analysis. Genetic principal components (PCs) were calculated
using EIGENSOFT (34); the first five PCs were used as covariates in the statistical models to control for
confounding due to population stratification in the samples, which included participants from multiple
race groups (88.5% were Caucasian). The five top PCs were determined from the scree plot since they
explain most of the variance (Fig. S2). The PC analysis steps are summarized in Text S1. Other covariates
such as hospitalization flag (inpatient or outpatient at the time of randomization into the trial [HOSPSTR])
and antibacterial drug treatment for CDI (ADT) flag (fidaxomicin, metronidazole, or vancomycin [ADT-
STR]) were included in the models, and the genotypes were coded to detect additive genetic effects.
Within each genetic variant, genotype was numerically coded for an individual participant as 0, 1, or 2
to reflect the number of copies of the minor allele. Treatment was numerically recoded as 0, 1, and 2
depending on whether, in addition to ADT, a participant received placebo, monotherapy (bezlotoxumab
alone), or combination therapy (actoxumab plus bezlotoxumab), respectively, since the clinical efficacy
results show a reduction of rCDI rates versus placebo while monotherapy and combination therapy have
an increasing or additive trend (17).
The full statistical model was logit(pi)  0  covXi  1  trti  2  gi  3  trti  gi, where
pi is the CDI recurrence rate for genotype or subject i and the Xi are subject i’s covariates (multiple
covariates) including HOSPSTR, ADTSTR, and PC1 to PC5. The comparative statistical model was
logit(pi)  0  covXi  1  trti.
A standard 2-df likelihood ratio-based test in a logistic regression model was used to test the joint
null hypothesis of no genotype main effect and no genotype-by-treatment interaction. Due to the
limited power of SNPs with low MAF, 7,570,264 SNPs with MAF of 1% were tested in this analysis. A
standard Bonferroni correction assuming 1 million independent SNPs was used for multiplicity adjust-
ment, so that SNPs with P 5 108 were considered to be genome-wide statistically significant in the
context of a maximum familywise type I error rate of 5%. In addition to the 2-df test, we also conducted
the 1-df tests in the treatment (BEZ and BEZ  ACT) arms and placebo arm separately to help interpret
the overall association results. The full statistical model and the comparative statistical model are the
same as described above except that the treatment term and the genotype-by-treatment interaction
term should be dropped in the full statistical model and the treatment term should be dropped in the
comparative statistical model.
Prior studies have indicated a link between immune response and protection from rCDI, with a serum
antibody response to C. difficile toxins being associated with subsequent protection from recurrence (28).
Furthermore, a study in MHC class II knockout mice and CD4 T-cell knockout mice found that protection
from rCDI requires MHC class II genes and is dependent on T-cell help (29). Because of the prior evidence
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linking immune response with rCDI, we conducted HLA association analyses in the xMHC as a separate
candidate gene study including the analysis of the three class I genes (HLA-A, HLA-B, and HLA-C) and four
class II genes (HLA-DRB1, HLA-DQA1, HLA-DQB1, and HLA-DPB1). The statistical association analysis
method for HLA alleles was the same as that described above for GWAS SNPs. A total of 112 out of 219
imputed HLA alleles with MAF of 1% were tested in this analysis. Bonferroni correction was used for
multiplicity adjustment, and the P value threshold for statistical significance was set at 4.46 104
(0.05/112) for HLA association analysis.
For SNPs or HLA alleles declared statistically significant with the 2-df joint test, a logistic regression-
based likelihood ratio test with 1 df was conducted separately in the bezlotoxumab-containing and
placebo arms to assess the association between rCDI and genotype. Effect sizes and ORs were further
reported. All statistical analyses were performed using PLINK (35) and R (36).
Subgroup analysis. Because bezlotoxumab is indicated for patients at high risk for rCDI, the
proportion of participants with rCDI was estimated for each treatment cohort by genotype and rCDI risk
category. Participants considered at high risk of rCDI were defined as those having one or more of the
following factors: prior episode of CDI in the past 6 months, severe CDI at baseline (per Zar score [37]),
age of 65 years, CDI due to a hypervirulent strain (027, 078, or 244 ribotypes), immunocompromised,
or receiving concomitant systemic antibiotics. Meanwhile, participants at low risk of rCDI were those with
none of the above risk factors. The risk difference and its 95% CI were calculated in the subgroups
stratified by minor allele/homozygote major allele carriers and high-/low-risk group of rCDI for compar-
ison.
Fine-mapping. To determine the probability of each SNP in LD with lead SNP rs2516513 being the
causal variant at the locus, we ran a simple fine-mapping script in R using GWAS summary statistics. This
method calculates approximate Bayes factors from effect sizes (betas) and standard errors (38). This
method also assumes that there is one causal variant and places equal priors on all variants (39). Because
the summary statistics were from a likelihood ratio test (LRT) with 2-df, we first converted the LRT P
values to betas and standard errors using the method from the R package ‘coloc’ (40). The 95% credible
set was very large (4,082 variants), likely due to the high number of variants in tight LD in this region.
There were 26 variants with posterior probability of 1%, including the lead variant rs2516513.
Causal gene analysis. To determine the possible causal gene driving the association at the
rs2516513 locus, we assessed whether the lead GWAS SNP or any SNP in high LD (r2  0.8) was a
significant eQTL, pQTL, or meth-QTL. Significance level was determined by each study, with the most
commonly used threshold being false discovery rate (FDR) of 0.05. Details of significance level
calculation and other analytical methods are provided in the indicated publications: eQTL data across 48
different tissues (41); eQTL data from CD14monocytes, CD16 neutrophils, and naive CD4 T cells (42);
meth-QTLs for CD14 monocytes, CD16 neutrophils, and naive CD4 T cells (genes identified that
overlap methylated regions) (42); eQTL data from gamma interferon-stimulated primary monocytes (43);
pQTL data from human plasma proteome (44).
Data availability. The data sharing policy of Merck Sharp & Dohme, including restrictions, is
available at http://engagezone.msd.com/ds_documentation.php. Requests for access to the GWAS sum-
mary statistics results from this clinical study can be submitted through the EngageZone site or via email
to dataaccess@merck.com.
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